{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T09:53:37Z","timestamp":1793267617622,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008484","name":"BioMarin Pharmaceutical Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.ymgme.2023.108114","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T15:15:01Z","timestamp":1702653301000},"page":"108114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria"],"prefix":"10.1016","volume":"141","author":[{"given":"Barbara K.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian E.","family":"Clague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary O.","family":"Harding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ece","family":"Kucuksayrac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew G.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lindstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Longo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Maillot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ania C.","family":"Muntau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto T.","family":"Zori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2023.108114_bb0005","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ymgme.2023.108114_bb0010","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","article-title":"The complete European guidelines on phenylketonuria: diagnosis and treatment","volume":"12","author":"van Wegberg","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2023.108114_bb0015","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/gim.2013.157","article-title":"Phenylalanine hydroxylase deficiency: diagnosis and management guideline","volume":"16","author":"Vockley","year":"2014","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2023.108114_bb0020","author":"BioMarin Pharmaceutical Inc."},{"key":"10.1016\/j.ymgme.2023.108114_bb0025","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2023.108114_bb0030","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ymgme.2014.11.011","article-title":"A randomized, placebo-controlled, double-blind study of sapropterin to treat ADHD symptoms and executive function impairment in children and adults with sapropterin-responsive phenylketonuria","volume":"114","author":"Burton","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0035","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.108114_bb0040","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jpeds.2008.11.040","article-title":"Efficacy of sapropterin dihydrochloride in increasing phenylalanine tolerance in children with phenylketonuria: a phase III, randomized, double-blind, placebo-controlled study","volume":"154","author":"Trefz","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2023.108114_bb0045","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.ymgme.2015.02.003","article-title":"Long-term safety and efficacy of sapropterin: the PKUDOS registry experience","volume":"114","author":"Longo","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s10198-021-01415-9","article-title":"The impact on quality of life of diet restrictions and disease symptoms associated with phenylketonuria: a time trade-off and discrete choice experiment study","volume":"23","author":"Olofsson","year":"2022","journal-title":"Eur. J. Health Econ."},{"key":"10.1016\/j.ymgme.2023.108114_bb0055","doi-asserted-by":"crossref","first-page":"561","DOI":"10.3389\/fpsyt.2019.00561","article-title":"Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments","volume":"10","author":"Ashe","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.ymgme.2023.108114_bb0060","author":"BioMarin Pharmaceutical Inc."},{"key":"10.1016\/j.ymgme.2023.108114_bb0065","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2023.108114_bb0070","article-title":"Use of pegvaliase in the management of phenylketonuria: case series of early experience in US clinics","volume":"28","author":"Adams","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108114_bb0075","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2022.08.001","article-title":"Pegvaliase dosing in adults with PKU: requisite dose for efficacy decreases over time","volume":"137","author":"Hollander","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0080","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ymgme.2021.05.006","article-title":"Palynziq clinic: one year and 43 patients later","volume":"133","author":"Lah","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0085","article-title":"First 1.5 years of pegvaliase clinic: experiences and outcomes","volume":"24","author":"Sacharow","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2023.108114_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ymgme.2021.06.002","article-title":"Nutrition status of adults with phenylketonuria treated with pegvaliase","volume":"133","author":"Viau","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0095","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2019.07.018","article-title":"Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria","volume":"128","author":"Zori","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0100","series-title":"Regression Modelling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"},{"key":"10.1016\/j.ymgme.2023.108114_bb0105","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.cct.2011.05.006","article-title":"Are propensity scores really superior to standard multivariable analysis?","volume":"32","author":"Biondi-Zoccai","year":"2011","journal-title":"Contemp Clin. Trials"},{"key":"10.1016\/j.ymgme.2023.108114_bb0110","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jacc.2016.10.060","article-title":"Comparison of propensity score methods and covariate adjustment: evaluation in 4 cardiovascular studies","volume":"69","author":"Elze","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ymgme.2023.108114_bb0115","series-title":"Biostatistics for Biomedical Research","article-title":"Modeling for observational treatment comparisons","author":"Harrell","year":"2022"},{"key":"10.1016\/j.ymgme.2023.108114_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0125","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.1002\/sim.7433","article-title":"Modeling continuous response variables using ordinal regression","volume":"36","author":"Liu","year":"2017","journal-title":"Stat. Med."},{"key":"10.1016\/j.ymgme.2023.108114_bb0130","first-page":"573","article-title":"Gini's mean difference rediscovered","volume":"55","author":"David","year":"1968","journal-title":"Biometrika."},{"key":"10.1016\/j.ymgme.2023.108114_bb0135","first-page":"285","article-title":"Gini's mean difference: a superior measure of variability for non-normal distributions","author":"Yitzhaki","year":"2003","journal-title":"Metron. LXI"},{"key":"10.1016\/j.ymgme.2023.108114_bb0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/ejcn.2010.258","article-title":"Blood phenylalanine control in phenylketonuria: a survey of 10 European centres","volume":"65","author":"Ahring","year":"2011","journal-title":"Eur. J. Clin. Nutr."},{"key":"10.1016\/j.ymgme.2023.108114_bb0145","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2017.01.001","article-title":"Adherence to clinic recommendations among patients with phenylketonuria in the United States","volume":"120","author":"Jurecki","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s10545-010-9073-y","article-title":"The reality of dietary compliance in the management of phenylketonuria","volume":"33","author":"MacDonald","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2023.108114_bb0155","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000342256","article-title":"Adherence issues in inherited metabolic disorders treated by low natural protein diets","volume":"61","author":"MacDonald","year":"2012","journal-title":"Ann. Nutr. Metab."},{"key":"10.1016\/j.ymgme.2023.108114_bb0160","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0140-6736(02)09334-0","article-title":"How practical are recommendations for dietary control in phenylketonuria?","volume":"360","author":"Walter","year":"2002","journal-title":"Lancet."},{"key":"10.1016\/j.ymgme.2023.108114_bb0165","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/cts.13043","article-title":"Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria","volume":"14","author":"Qi","year":"2021","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.ymgme.2023.108114_bb0170","series-title":"Fundamentals of Modern Statistical Methods: Substantially Improving Power and Accuracy","author":"Wilcox","year":"2010"},{"key":"10.1016\/j.ymgme.2023.108114_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0021403","article-title":"Problems with using the normal distribution--and ways to improve quality and efficiency of data analysis","volume":"6","author":"Limpert","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2023.108114_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11100680","article-title":"Differences of phenylalanine concentrations in dried blood spots and in plasma: erythrocytes as a neglected component for this observation","volume":"11","author":"Haas","year":"2021","journal-title":"Metabolites."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007448?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223007448?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:55:06Z","timestamp":1761090906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223007448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1096719223007448"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108114","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.108114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108114"}}